Introduction:　P2Y12　receptor　(P2Y12R)　is　a　G　protein-coupled　receptor　that　plays　a　crucial　role　in　regulating　platelet　activation　and　aggregation.　P2Y12R　is　involved　in　various　processes　such　as　renal　fibrosis,　cancer,　ischemic　disease,　and　related　complications,　making　it　an　appealing　target　for　therapeutic　interventions.　Over　the　past　decade,　the　discovery　and　development　of　P2Y12R　antagonists　have　significantly　advanced,　offering　novel　treatment　options　that　improve　clinical　outcomes.　Areas　covered:　This　review　covers　P2Y12R　antagonists　reported　in　patents　issued　in　the　online　databases　of　the　World　Intellectual　Property　Organization　and　the　European　Patent　Office　from　2019　to　2024.　This　review　introduces　the　development　of　existing　antagonists　and　evaluates　the　therapeutic　potential　of　these　compounds.　Expert　opinion:　Reversible　P2Y12R　antagonists　offer　a　potentially　safer　alternative　to　the　currently　dominant　irreversible　antagonists　on　the　market,　as　they　allow　for　more　controlled　platelet　inhibition　and　can　reduce　the　toxicity　and　adverse　effects　associated　with　conventional　drugs.　Importantly,　the　integration　of　computational　drug　design　and　molecular　docking　studies　in　the　discovery　and　optimization　of　P2Y12R　antagonists　represents　a　significant　advancement　in　precision　medicine.　This　not　only　provides　valuable　structural　scaffolds　but　also　stimulates　novel　ideas　for　developing　promising　drugs　that　are　both　safe　and　efficacious.　©　2025　Informa　UK　Limited,　trading　as　Taylor　&　Francis　Group.